Burger RA, et al. - In patients with persistent or recurrent ovarian carcinoma and related malignancies, the effectiveness of dalantercept (a soluble ALK1 inhibitor receptor fusion protein) was evaluated. Measurable disease, 1-2 prior cytotoxic regimens and Gynecologic Oncology Group performance status ≤ 2 was the included eligibility criteria. For this analysis, dalantercept was administered subcutaneously at 1.2 mg/kg every 3 weeks until disease progression or development of unacceptable toxicity. In this patient population, dalantercept was noted to be safe but had limited efficacy. Ultimately, all participants discontinued dalantercept, 24 (80.0%) due to progression, 5 (16.7%) due to toxicity, and 1 (3.3%) for other reasons.